RET-protooncogene variants in patients with sporadic neoplasms of the digestive tract and the central nervous system
- 182 Downloads
- 4 Citations
Abstract
Purpose
The RET protooncogene plays a crucial role in neural crest development; accordingly, mutations of RET cause MEN2A and familial medullary thyroid carcinoma, while the expression deregulation of RET is involved in the pathophysiology of glioblastoma multiforme (GBM) and pancreatic cancer (PDAC). The aim of this study was to evaluate if germline variants of the RET protooncogene are associated with GBM, pancreatic cancer and gastric cancer (GC).
Methods
Genomic DNA from peripheral blood was isolated from 100 patients with GBM, 65 patients with GC and 54 patients with PDAC. The coding sequence of RET promoter, exon 2 and exon 13 was amplified. Sequence variations at −5 and −1 in the promotor and in exon 2 were determined through a LightCycler assay, and analysis of exon 13 was carried out by genomic sequencing.
Results
There was no significant association of the RET-promoter or exon 2 genotypes with the phenotype in the different populations, although there was an increase of the GG genotype of the −5G>A variant in all cancers compared to controls. Sequencing of exon 13 identified mutation c.2372A>T in codon 791 (Y791F) in heterozygous state in one of 100 GBM patients, in two of 65 patients with gastric cancer, in two of 54 PDAC patients and in none of the controls.
Conclusions
Although our data did not reach significance in our small cohorts, we cannot rule out the involvement of the −5G promoter allele and the c.2372A>T mutation in the development of the aforementioned tumours.
Keywords
RET protooncogene Pancreatic cancer Gastric cancer Glioblastoma multiformeNotes
Conflict of interest
Parts of this study were presented as poster at the 12th Annual Meeting on Surgical Research (Chirurgische Forschungstage) in Freiburg, Germany, and as oral presentation in the 122nd Congress of the “Deutsche Gesellschaft für Chirurgie”.
References
- 1.Panetta D, Yin L, Barale R, Romeo G, Ravazzolo R, Ceccherini I, Puliti A (2001) Genomic organisation of the mouse Ret proto-oncogene. DNA Seq 11:501–506PubMedGoogle Scholar
- 2.Kwok JB, Gardner E, Warner JP, Ponder BA, Mulligan LM (1993) Structural analysis of the human ret proto-oncogene using exon trapping. Oncogene 8:2575–2582PubMedGoogle Scholar
- 3.Fitze G, Appelt H, Konig IR, Gorgens H, Stein U, Walther W, Gossen M, Schreiber M, Ziegler A, Roesner D, Schackert HK (2003) Functional haplotypes of the RET proto-oncogene promoter are associated with Hirschsprung disease (HSCR). Hum Mol Genet 12:3207–3214PubMedCrossRefGoogle Scholar
- 4.Donis-Keller H (1995) The RET proto-oncogene and cancer. J Intern Med 238:319–325PubMedCrossRefGoogle Scholar
- 5.Berndt I, Reuter M, Saller B, Frank-Raue K, Groth P, Grussendorf M, Raue F, Ritter MM, Hoppner W (1998) A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 83:770–774PubMedCrossRefGoogle Scholar
- 6.Fitze G, Schierz M, Bredow J, Saeger HD, Roesner D, Schackert HK (2002) Various penetrance of familial medullary thyroid carcinoma in patients with RET protooncogene codon 790/791 germline mutations. Ann Surg 236:570–575PubMedCrossRefGoogle Scholar
- 7.Griseri P, Bachetti T, Puppo F, Lantieri F, Ravazzolo R, Devoto M, Ceccherini I (2005) A common haplotype at the 5′ end of the RET proto-oncogene, overrepresented in Hirschsprung patients, is associated with reduced gene expression. Hum Mutat 25:189–195PubMedCrossRefGoogle Scholar
- 8.Emison ES, McCallion AS, Kashuk CS, Bush RT, Grice E, Lin S, Portnoy ME, Cutler DJ, Green ED, Chakravarti A (2005) A common sex-dependent mutation in a RET enhancer underlies Hirschsprung disease risk. Nature 434:857–863PubMedCrossRefGoogle Scholar
- 9.Magalhaes PK, de Castro M, Elias LL, Soares EG, Maciel LM (2004) Polymorphisms in the RET proto-oncogene and the phenotypic presentation of familial medullary thyroid carcinoma. Thyroid 14:848–852PubMedGoogle Scholar
- 10.Sawai H, Okada Y, Kazanjian K, Kim J, Hasan S, Hines OJ, Reber HA, Hoon DS, Eibl G (2005) The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling. Cancer Res 65:11536–11544PubMedCrossRefGoogle Scholar
- 11.Okada Y, Takeyama H, Sato M, Morikawa M, Sobue K, Asai K, Tada T, Kato T, Manabe T (1999) Experimental implication of celiac ganglionotropic invasion of pancreatic-cancer cells bearing c-ret proto-oncogene with reference to glial-cell-line-derived neurotrophic factor (GDNF). Int J Cancer 81:67–73PubMedCrossRefGoogle Scholar
- 12.Ceyhan GO, Giese NA, Erkan M, Kerscher AG, Wente MN, Giese T, Buchler MW, Friess H (2006) The neurotrophic factor artemin promotes pancreatic cancer invasion. Ann Surg 244:274–281PubMedCrossRefGoogle Scholar
- 13.Funahashi H, Okada Y, Sawai H, Takahashi H, Matsuo Y, Takeyama H, Manabe T (2005) The role of glial cell line-derived neurotrophic factor (GDNF) and integrins for invasion and metastasis in human pancreatic cancer cells. J Surg Oncol 91:77–83PubMedCrossRefGoogle Scholar
- 14.Zeng Q, Cheng Y, Zhu Q, Yu Z, Wu X, Huang K, Zhou M, Han S, Zhang Q (2008) The relationship between overexpression of glial cell-derived neurotrophic factor and its RET receptor with progression and prognosis of human pancreatic cancer. J Int Med Res 36:656–664PubMedGoogle Scholar
- 15.Wiesenhofer B, Stockhammer G, Kostron H, Maier H, Hinterhuber H, Humpel C (2000) Glial cell line-derived neurotrophic factor (GDNF) and its receptor (GFR-alpha 1) are strongly expressed in human gliomas. Acta Neuropathol 99:131–137PubMedCrossRefGoogle Scholar
- 16.Ikeda I, Ishizaka Y, Tahira T, Suzuki T, Onda M, Sugimura T, Nagao M (1990) Specific expression of the ret proto-oncogene in human neuroblastoma cell lines. Oncogene 5:1291–1296PubMedGoogle Scholar
- 17.Gorgens H, Fitze G, Roesner D, Schackert HK (2004) One-step analysis of ten functional haplotype combinations of the basic RET promoter with a LightCycler assay. Clin Chem 50:1693–1695PubMedCrossRefGoogle Scholar
- 18.Ceccherini I, Hofstra RM, Luo Y, Stulp RP, Barone V, Stelwagen T, Bocciardi R, Nijveen H, Bolino A, Seri M et al (1995) DNA polymorphisms and conditions for SSCP analysis of the 20 exons of the ret proto-oncogene. Oncogene 10:1257PubMedGoogle Scholar
- 19.Borrego S, Saez ME, Ruiz A, Gimm O, Lopez-Alonso M, Antinolo G, Eng C (1999) Specific polymorphisms in the RET proto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression. J Med Genet 36:771–774PubMedGoogle Scholar
- 20.Plaza Menacho I, Koster R, van der Sloot AM, Quax WJ, Osinga J, van der Sluis T, Hollema H, Burzynski GM, Gimm O, Buys CH, Eggen BJ, Hofstra RM (2005) RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor. Cancer Res 65:1729–1737PubMedCrossRefGoogle Scholar
- 21.Songyang Z, Carraway KL 3rd, Eck MJ, Harrison SC, Feldman RA, Mohammadi M, Schlessinger J, Hubbard SR, Smith DP, Eng C et al (1995) Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature 373:536–539PubMedCrossRefGoogle Scholar
- 22.Ceccherini I, Hofstra RM, Luo Y, Stulp RP, Barone V, Stelwagen T, Bocciardi R, Nijveen H, Bolino A, Seri M et al (1994) DNA polymorphisms and conditions for SSCP analysis of the 20 exons of the ret protooncogene. Oncogene 9(10):3025–3029 Google Scholar
- 23.Mulligan LM, Eng C, Healey CS, Ponder MA, Feldman GL, Li P, Jackson CE, Ponder BA (1994) A de novo mutation of the RET proto-oncogene in a patient with MEN 2A. Hum Mol Genet 3(6):1007–1008Google Scholar